About: Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies and public health implications

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies and public health implications Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies and public health implications
Creator	Caini, Saverio Paget, John Bellerba, Federica Corso, Federica Díaz-Basabe, Angélica Facciotti, Federica Gandini, Sara Mazzarella, Luca Natoli, Gioacchino Palli, Domenico Pelicci, Pier Raimondi, Sara Vineis, Paolo
Source	MedRxiv
abstract	Serology-based tests have become a key public health element in the COVID-19 pandemic to assess the degree of herd immunity that has been achieved in the population. These tests differ between one another in several ways. Here, we conducted a systematic review and meta-analysis of the diagnostic accuracy of currently available SARS-CoV-2 serological tests, and assessed their real-world performance under scenarios of varying proportion of infected individuals. We included independent studies that specified the antigen used for antibody detection and used quantitative methods. We identified nine independent studies, of which six were based on commercial ELISA or CMIA/CLIA assays, and three on in-house tests. Test sensitivity ranged from 68% to 93% for IgM, from 65% to 100% for IgG, and from 83% to 98% for total antibodies. Random-effects models yielded a summary sensitivity of 82% (95%CI 75-88%) for IgM, and 85% for both IgG (95%CI 73-93%) and total antibodies (95%CI 74-94%). Specificity was very high for most tests, and its pooled estimate was 98% (95%CI 92-100%) for IgM and 99% (95%CI 98-100%) for both IgG and total antibodies. The heterogeneity of sensitivity and specificity across tests was generally high (I2[≤]50%). In populations with a low prevalence ([≤]5%) of seroconverted individuals, the positive predictive value would be [≤]88% for most assays, except those reporting perfect specificity. Our data suggest that the use of serological tests for large-scale prevalence surveys (or to grant %22immunity passports%22) are currently only justified in hard-hit regions, while they should be used with caution elsewhere.
has issue date	2020-05-08(xsd:dateTime)
bibo:doi	10.1101/2020.05.03.20084160
has license	medrxiv
sha1sum (hex)	4b2eaa00031eb35c045d9b64211634e3ec644ff1
schema:url	https://doi.org/10.1101/2020.05.03.20084160
resource representing a document's title	Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies and public health implications
resource representing a document's body	covid:4b2eaa00031eb35c045d9b64211634e3ec644ff1#body_text
is schema:about of	named entity 'IgG' named entity 'performance' named entity 'assess' named entity 'assessed' named entity 'IgG' named entity 'assays' named entity 'tests' named entity 'Title' named entity 'TEST SENSITIVITY' named entity 'A45' named entity 'ANTIBODY DETECTION' named entity 'CURRENTLY' named entity 'PERFORMANCE' named entity 'pandemic' named entity 'SARS-CoV-2' named entity 'IgM' named entity 'IgG' named entity 'generally' named entity 'heterogeneity' named entity 'tests' named entity 'Here' named entity 'COVID-19' named entity 'herd immunity' named entity 'sensitivity and specificity' named entity 'independent studies' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'IgM' named entity 'antibodies' named entity 'heterogeneity' named entity 'IgM' named entity 'Serology' named entity 'CLIA' named entity 'SARS-CoV-2' named entity 'Meta-analysis' named entity 'SARS-CoV-2' named entity 'antibody' named entity 'IgG' named entity 'Serology' named entity 'preprint' named entity 'serological tests' named entity 'serological tests' named entity 'preprint' named entity 'DOR' named entity 'DOR' named entity 'antibody' named entity 'IgM' named entity 'preprint' named entity 'diagnostic odds ratio' named entity 'non-medical' named entity 'serology' named entity 'COVID' named entity 'medRxiv' named entity 'IgM' named entity 'quantitative methods' named entity 'SARS-CoV-2' named entity 'Beijing' named entity 'IgG' named entity 'asymptomatic' named entity 'diagnostic accuracy' named entity 'IgG' named entity 'correlation' named entity 'preprint' named entity 'peer review' named entity 'infection' named entity 'preprint' named entity 'immunological tests' named entity 'serological tests' named entity 'seroconverted' named entity 'predictive values' named entity 'antigens' named entity 'antibodies' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software